<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00022399</url>
  </required_header>
  <id_info>
    <org_study_id>J0007</org_study_id>
    <secondary_id>P50CA058236</secondary_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>CDR0000068812</secondary_id>
    <secondary_id>00-03-08-01</secondary_id>
    <secondary_id>NCI-N01-95129</secondary_id>
    <secondary_id>NCI-P01-0186</secondary_id>
    <nct_id>NCT00022399</nct_id>
  </id_info>
  <brief_title>Celecoxib Compared With No Treatment Before Surgery in Treating Patients With Localized Prostate Cancer</brief_title>
  <official_title>A Randomized, Placebo-Controlled Trial Of Celecoxib In Men Pre-Prostatectomy For Clinically Localized Adenocarcinoma Of The Prostate: Evaluation Of Drug-Specific Biomarker Modulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Celecoxib may be an effective treatment for early stage prostate cancer. It is not&#xD;
      yet known if celecoxib is more effective than no treatment before surgery for prostate&#xD;
      cancer.&#xD;
&#xD;
      PURPOSE: Randomized phase I trial to determine the effectiveness of celecoxib given before&#xD;
      surgery to remove the prostate in treating patients who have localized prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare biomarker modulation (prostaglandin levels) in tissue samples of patients with&#xD;
           localized prostate cancer treated with neoadjuvant celecoxib vs placebo followed by&#xD;
           prostatectomy.&#xD;
&#xD;
        -  Compare the effect of these regimens on angiogenic factors within the prostate in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the pharmacokinetic and pharmacodynamic effects of celecoxib in these&#xD;
           patients.&#xD;
&#xD;
        -  Compare the toxicity profiles of these regimens in these patients.&#xD;
&#xD;
        -  Compare the compliance of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are&#xD;
      randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral neoadjuvant celecoxib twice daily.&#xD;
&#xD;
        -  Arm II: Patients receive oral neoadjuvant placebo twice daily. Treatment in both arms&#xD;
           continues for at least 4 weeks followed by prostatectomy.&#xD;
&#xD;
      Patients are followed within 1 month and then at 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 60-70 patients (at least 30 per arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 25, 2002</start_date>
  <completion_date type="Actual">January 31, 2005</completion_date>
  <primary_completion_date type="Actual">January 31, 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Celecoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive celecoxib 400mg by mouth twice daily for 4 to 6 weeks prior to standard-of-care prostatectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive placebo for 4 to 6 weeks prior to standard-of-care prostatectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
    <description>400mg PO twice daily for 4-6 weeks up to 8 hours prior to prostatectomy.</description>
    <arm_group_label>Celecoxib</arm_group_label>
    <other_name>celebrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo PO twice daily for 4-6 weeks up to 8 hours prior to prostatectomy.</description>
    <arm_group_label>Placebo-control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed localized adenocarcinoma of the prostate&#xD;
             with one or more of the following:&#xD;
&#xD;
               -  Gleason sum at least 7&#xD;
&#xD;
               -  Prostate-specific antigen (PSA) at least 15 ng/mL&#xD;
&#xD;
               -  Clinical stage T2b or T2c (stage II)&#xD;
&#xD;
               -  Any combination of PSA, clinical stage, or Gleason sum with an estimated risk of&#xD;
                  capsular penetration greater than 45%&#xD;
&#xD;
          -  At least 3 positive core biopsies&#xD;
&#xD;
          -  Planned radical prostatectomy&#xD;
&#xD;
          -  No metastatic disease secondary to prostate cancer&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC greater than 3,000/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 9 g/dL&#xD;
&#xD;
          -  No history of bleeding disorders&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 1.5 mg/dL&#xD;
&#xD;
          -  AST/ALT less than 1.5 times upper limit of normal&#xD;
&#xD;
          -  No viral hepatitis&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance at least 50 mL/min&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No history of hypersensitivity and/or adverse reactions to salicylates&#xD;
&#xD;
          -  No allergy to sulfa-containing medications&#xD;
&#xD;
          -  No other active malignancy within the past 5 years except superficial bladder cancer&#xD;
             or nonmelanoma skin cancer&#xD;
&#xD;
          -  No medical or psychiatric problem that would preclude study participation&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior immunologic therapy for prostate cancer&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy and recovered&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No prior androgen ablation for prostate cancer&#xD;
&#xD;
          -  At least 4 weeks since prior hormonal therapy and recovered&#xD;
&#xD;
          -  At least 30 days since prior chronic use (more than 3 times per week for more than 2&#xD;
             weeks) of glucocorticoids&#xD;
&#xD;
          -  No concurrent glucocorticoids&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy to the pelvis or surrounding tissues and&#xD;
             recovered&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery and recovered&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior investigational therapy for prostate cancer&#xD;
&#xD;
          -  No prior or concurrent chronic anticoagulants&#xD;
&#xD;
          -  No prior cyclo-oxygenase-2 inhibitor therapy (e.g., rofecoxib or celecoxib)&#xD;
&#xD;
          -  At least 4 weeks since prior initiation of vitamins (except multivitamin) or herbs&#xD;
             with known effects on prostate function (PSA)&#xD;
&#xD;
          -  At least 30 days since prior chronic use (more than 3 times per week for more than 2&#xD;
             weeks) of aspirin (greater than 100 mg/day) or non-steroidal anti-inflammatory drugs&#xD;
             (NSAIDs)&#xD;
&#xD;
          -  At least 24 hours since prior use and no concurrent use of any of the following:&#xD;
&#xD;
               -  Over-the-counter (OTC) or prescription products containing aspirin or NSAIDs; OTC&#xD;
                  products containing bismuth subsalicylate, sodium salicylate, and/or magnesium&#xD;
                  salicylate; choline salicylate; ranitidine; cimetidine; famotidine; or&#xD;
                  lansoprazole&#xD;
&#xD;
          -  No aspirin (100 mg/day) within 1 week prior to surgery&#xD;
&#xD;
          -  No concurrent addition of vitamins or herbal supplements&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael A. Carducci, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Antonarakis ES, Heath EI, Walczak JR, Nelson WG, Fedor H, De Marzo AM, Zahurak ML, Piantadosi S, Dannenberg AJ, Gurganus RT, Baker SD, Parnes HL, DeWeese TL, Partin AW, Carducci MA. Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol. 2009 Oct 20;27(30):4986-93. doi: 10.1200/JCO.2009.21.9410. Epub 2009 Aug 31.</citation>
    <PMID>19720908</PMID>
  </results_reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>August 10, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>February 6, 2019</last_update_submitted>
  <last_update_submitted_qc>February 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage IIB prostate cancer</keyword>
  <keyword>stage IIA prostate cancer</keyword>
  <keyword>adenocarcinoma of the prostate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

